Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

MYSTIC: Developing biomarkers for metastatic NSCLC

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
MYSTIC: Developing biomarkers for metastatic NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
11 Apr 2019

Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma

Prof Sandip Patel - UC San Diego, San Diego, USA
Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma ( Prof Sandip Patel - UC San Diego, San Diego, USA )
11 Apr 2019

Latest updates in melanoma research

Dr Alexander van Akkooi - The Netherlands Cancer Institute, Amsterdam, Netherlands
Latest updates in melanoma research ( Dr Alexander van Akkooi - The Netherlands Cancer Institute, Amsterdam, Netherlands )
21 Mar 2019

Gynaecological cancer: Where are we now?

Dr Nelleke Ottevanger - Radboud University Medical Center, Nijmegen, Netherlands
Gynaecological cancer: Where are we now? ( Dr Nelleke Ottevanger - Radboud University Medical Center, Nijmegen, Netherlands )
21 Mar 2019

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer

Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA
Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer ( Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA )
19 Feb 2019

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma

Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma ( Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )
19 Feb 2019

CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma

Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA
CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma ( Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA )
16 Feb 2019

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
14 Feb 2019

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
14 Feb 2019

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Dr Arjun Balar - NYU Langone Health, New York City, USA
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ( Dr Arjun Balar - NYU Langone Health, New York City, USA )
14 Feb 2019